{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:20:24Z","timestamp":1785943224451,"version":"3.56.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Grants-in-Aid for Scientific Research Program","doi-asserted-by":"crossref","award":["23 EA1035"],"award-info":[{"award-number":["23 EA1035"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Quality indicators for supportive cancer care remain unclear. In this study, we aimed to clarify quality indicators for supportive care addressing side effects experienced by patients undergoing treatment from the perspectives of oncologists and pharmacists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a three-round modified Delphi study, including online discussions, to develop indicators for supportive care related to treatment-associated side effects in adult patients with cancer. An initial list of indicators was developed from a systematic review, conducted based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement, to identify existing quality indicators for managing treatment-induced toxicities in adult patients with cancer. Panelists were oncologists or pharmacists with at least 5\u00a0years of experience providing care to patients with cancer. Panelists evaluated the importance of each indicator using a 4-point Likert scale. Indicators rated as \u201cstrongly agree\u201d or \u201cagree\u201d by at least two-thirds of participants were adopted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 11 panel members (three oncologists and eight pharmacists) participated. In Round 1, 25 potential indicators were reviewed, six new indicators were proposed, and the scope of three indicators was revised (response rate: 100%). In Round 2, all indicators were re-examined, with 11 indicators receiving responses of \u201cstrongly agree\u201d or \u201cagree\u201d from all participants (response rate: 100%). In Round 3, conducted via an online meeting, 24 indicators were ultimately adopted (response rate: 81.8%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study identified 24 indicators for supportive care, particularly process indicators, from the perspectives of oncologists and pharmacists. Further research is needed to develop indicators relevant to patients and families.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag064","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:52:01Z","timestamp":1775130721000},"page":"976-983","source":"Crossref","is-referenced-by-count":0,"title":["Developing quality indicators for supportive care in cancer treatment: a modified Delphi method"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4732-3272","authenticated-orcid":false,"given":"Ayako","family":"Okuyama","sequence":"first","affiliation":[{"name":"Graduate School of Nursing Science, Graduate School of Public Health, St. Luke\u2019s International University , 10-1 Akashi-cho, Chuo-ku Tokyo 104-0044 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Hospital East , 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0421-5805","authenticated-orcid":false,"given":"Sadamoto","family":"Zenda","sequence":"additional","affiliation":[{"name":"Department of Supportive and Palliative Care Research Support Office, National Cancer Center Hospital East , 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2026080510413988800_ref1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/bcp.14159","article-title":"Serious adverse effects occurring after chemotherapy: a general cancer registry-based incidence survey","volume":"86","author":"Ingrand","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2026080510413988800_ref2","doi-asserted-by":"publisher","first-page":"e968","DOI":"10.1634\/theoncologist.2018-0476","article-title":"Adverse drug reactions in an oncological population: prevalence, predictability, and preventability","volume":"24","author":"Lavan","year":"2019","journal-title":"Oncologist"},{"key":"2026080510413988800_ref3","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jamaoncol.2019.0086","article-title":"Treatment-related complications of systemic therapy and radiotherapy","volume":"5","author":"Jairam","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026080510413988800_ref4","volume-title":"Latest cancer statistics","author":"National Cancer Center [Internet]"},{"key":"2026080510413988800_ref5","volume-title":"Designated cancer care hospitals","author":"Ministry of Health, Labour, and Welfare, Japan"},{"key":"2026080510413988800_ref6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/cas.12837","article-title":"Monitoring and evaluating the quality of cancer care in Japan using administrative claims data","volume":"107","author":"Iwamoto","year":"2016","journal-title":"Cancer Sci"},{"key":"2026080510413988800_ref7","volume-title":"Quality indicator project","author":"National Cancer Center, Japan"},{"key":"2026080510413988800_ref8","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1200\/JOP.2013.001237","article-title":"Evaluating the quality of supportive oncology using patient-reported data","volume":"10","author":"Dy","year":"2014","journal-title":"J Oncol Pract"},{"key":"2026080510413988800_ref9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12885-025-13519-z","article-title":"Quality indicators of supportive care for patients with cancer undergoing treatment: a systematic review","volume":"25","author":"Okuyama","year":"2025","journal-title":"BMC Cancer"},{"key":"2026080510413988800_ref10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/ajco.13917","article-title":"Measurement that matters: a systematic review and modified Delphi of multidisciplinary colorectal cancer quality indicators","volume":"20","author":"Donnelly","year":"2023","journal-title":"Asia Pac J Clin Oncol"},{"key":"2026080510413988800_ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020476","article-title":"Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review","volume":"6","author":"Boulkedid","year":"2011","journal-title":"PLoS One"},{"key":"2026080510413988800_ref12","volume-title":"Rand methodological guidance for conducting and critically appraising Delphi panels 2023","author":"Khodyakov"},{"key":"2026080510413988800_ref13","volume-title":"The RAND\/UCLA appropriateness method user's manual 2001","author":"Fitch"},{"key":"2026080510413988800_ref14","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jjco\/hyab008","article-title":"Establishment of a research policy for supportive and palliative care in Japan","volume":"51","author":"Zenda","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"2026080510413988800_ref15","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1200\/JOP.18.00390","article-title":"Evaluating the impact of treatment care planning on quality measures","volume":"15","author":"Rocque","year":"2019","journal-title":"J Oncol Pract"},{"key":"2026080510413988800_ref16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/annonc\/mdx757","article-title":"European Society for Medical Oncology (ESMO) position paper on supportive and palliative care","volume":"29","author":"Jordan","year":"2018","journal-title":"Ann Oncol"},{"key":"2026080510413988800_ref17","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1200\/JCO.24.00542","article-title":"Palliative care for patients with cancer: ASCO guideline update","volume":"42","author":"Sanders","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026080510413988800_ref18","volume-title":"Research to support the equalization of supportive care practices among designated cancer care hospitals and affiliated institutions","author":"Zenda","year":"2022"},{"key":"2026080510413988800_ref19","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1182\/bloodadvances.2020002314","article-title":"Guideline-based indicators for adult patients with myelodysplastic syndromes","volume":"4","author":"Stojkov","year":"2020","journal-title":"Blood Adv"},{"key":"2026080510413988800_ref20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11060-022-03971-3","article-title":"Quality indicators in neuro-oncology: review of the literature and development of a new quality indicator set for glioma care through a two-round Delphi survey","volume":"157","author":"Vanhauwaert","year":"2022","journal-title":"J Neuro-Oncol"},{"key":"2026080510413988800_ref21","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1007\/s10147-025-02894-z","article-title":"Real-world adherence to antiemetic guidelines in Japanese patients receiving high or carboplatin-based moderate emetic risk chemotherapy","volume":"30","author":"Okuyama","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"2026080510413988800_ref22","doi-asserted-by":"publisher","first-page":"e1482","DOI":"10.1002\/cnr2.1482","article-title":"Real-world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: a study based on a nationwide database cancer rep","volume":"5","author":"Okuyama","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"key":"2026080510413988800_ref23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00520-024-08623-y","article-title":"Outcomes of chemotherapy-induced nausea and vomiting guideline adherence in pediatric and adult patients: a systematic review","volume":"32","author":"Renaux Torres","year":"2024","journal-title":"Support Care Cancer"},{"key":"2026080510413988800_ref24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/intqhc\/mzv042","article-title":"Developing a set of quality indicators for breast cancer care in China","volume":"27","author":"Bao","year":"2015","journal-title":"Int J Qual Health Care"},{"key":"2026080510413988800_ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjqcco\/qcac070","article-title":"European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment","volume":"9","author":"Lee","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026080510413988800_ref26","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/8\/976\/68130642\/hyag064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/8\/976\/68130642\/hyag064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:41:49Z","timestamp":1785940909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/8\/976\/8660387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4,22]]},"published-print":{"date-parts":[[2026,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag064","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,4,22]]}}}